BC Innovations | Jun 9, 2016
Distillery Therapeutics

Therapeutics: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)

Other INDICATION: Progeria Patient sample, cell culture and mouse studies suggest promoting NFE2L2 activity could help treat Hutchinson-Gilford progeria syndrome (HGPS). In patient fibroblasts, NFE2L2 activity was lower than in fibroblasts from healthy volunteers. Also...
BC Extra | May 24, 2016
Company News

Arbor acquiring XenoPort

Specialty pharma Arbor Pharmaceuticals Inc. (Atlanta, Ga.) is acquiring XenoPort Inc. (NASDAQ:XNPT) for $7.03 per share, or about $467 million. The deal will give Arbor rights to Horizant gabapentin enacarbil , which is approved in the...
BC Week In Review | Apr 4, 2016
Company News

XenoPort, Dr. Reddy’s Laboratories Ltd. deal

XenoPort granted Dr. Reddy’s exclusive, U.S. rights to develop and commercialize XP23829 . XenoPort will receive $47.5 million up front and is eligible for up to $190 million in regulatory milestones and $250 million in commercial...
BC Extra | Mar 29, 2016
Company News

Dr. Reddy's, XenoPort strike deal for psoriasis therapy

XenoPort Inc. (NASDAQ:XNPT) granted Dr. Reddy%27s Laboratories Ltd. (NYSE:RDY) exclusive, U.S. rights to develop and commercialize XP23829 , which has completed a Phase II trial to treat moderate to severe chronic plaque-type psoriasis. The compound is...
BioCentury | Jan 4, 2016
Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the charge...
BC Week In Review | Oct 12, 2015
Clinical News

XP23829: Development discontinued

XenoPort discontinued development of XP23829 and plans to partner the compound and other pipeline candidates to focus on commercializing Horizant gabapentin enacarbil. In September, XenoPort reported data from a Phase II trial of XP23829 to...
BC Week In Review | Oct 12, 2015
Company News

XenoPort neurology, autoimmune news

XenoPort will reduce headcount by 25 (14%) to about 155 and plans to partner XP23829 and other pipeline candidates to focus on commercializing Horizant gabapentin enacarbil. Cuts include positions related to the XP23829 program. Additionally,...
BC Innovations | Oct 8, 2015
Distillery Therapeutics

Therapeutics: Kelch-like ECH-associated protein 1 (KEAP1); nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)

Hematology INDICATION: Sickle cell disease Mouse studies suggest inhibiting KEAP1 or activating NFE2L2 could help treat sickle cell disease. In a mouse model of sickle cell disease, KEAP1 knockdown increased NFE2L2 levels in the liver...
BC Extra | Oct 2, 2015
Company News

XenoPort gains on restructuring plans

XenoPort Inc. (NASDAQ:XNPT) gained $0.84 (24%) to $4.32 after the company said it is replacing its CEO and plans to partner XP23829 and other pipeline candidates to focus on commercializing Horizant gabapentin enacarbil . EVP and...
BC Week In Review | Sep 21, 2015
Clinical News

XP23829: Phase II data

XenoPort Inc. (NASDAQ:XNPT), Santa Clara, Calif.   Product: XP23829   Business: Autoimmune   Molecular target: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) (NRF2)   Description: Oral prodrug of monomethyl fumarate (MMF) that induces and activates the...
Items per page:
1 - 10 of 35